40 Researchers in Germany have uncovered a complex system within the cell nucleus that helps explain how cancer cells turn on harmful genes. The study points to a breakdown in the usual communication between genetic enhancers and promoters, a process that is supposed to be tightly regulated. When this communication system goes awry, it can lead to the unchecked activation of cancer-driving genes. The findings were published in the International Journal of Cancer. The findings focus on how the physical structure of DNA inside the cell nucleus influences which genes are expressed. Enhancers are stretches of non-coding DNA that help switch on specific genes, often from far away. Promoters are the starting points of genes themselves. Normally, the two coordinate with precision, aided by proteins and the organisation of DNA into loops and compartments. In cancer cells, however, this architecture becomes distorted. One cause is structural rearrangements in the genome, such as translocations and deletions. These alterations can result in “enhancer hijacking”, where powerful enhancers are mistakenly positioned near genes that promote tumour growth. This rewiring enables abnormal gene activation that would not occur in a healthy cell. The study also highlights the role of extrachromosomal DNA (ecDNA), which exists outside the main chromosomes. Unlike regular DNA, ecDNA is more accessible and can carry multiple copies of cancer genes alongside enhancers. These mobile DNA circles can form hubs that link enhancers and promoters in ways not normally possible. The result is a dramatic increase in the activity of oncogenes. Adding another layer of complexity, scientists describe the presence of “onco-condensates” – dense clusters of proteins and RNA that form in the nucleus. These structures gather components involved in gene regulation, including transcription factors and RNA polymerase II. In cancer cells, onco-condensates can arise due to mutations or overexpression of certain proteins, leading to further activation of genes that drive cancer progression. One of the striking implications of the research is how these three processes – genomic rearrangements, ecDNA formation, and onco-condensates – can intersect. In some cancers, fusion proteins generated by genetic alterations can both reshape DNA organisation and promote the formation of condensates. This double effect may create hotspots of regulatory activity that fuel tumour growth. Understanding these mechanisms offers new opportunities for treatment. Targeting the components of onco-condensates, blocking enhancer-promoter miscommunication, or disrupting the function of ecDNA could all be potential strategies. Some experimental drugs are already being tested to interfere with these pathways, particularly in cancers resistant to standard therapies. The work underscores how cancer is not only a disease of mutations, but also of miscommunication at the molecular level. Rather than changes to the DNA code alone, it is the breakdown of structural and regulatory systems that allows tumours to thrive. By focusing on these overlooked aspects of cancer biology, researchers hope to uncover more effective and precise ways to combat the disease.